Clinical trials: Throat Carcinoma
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
Patients have a type of a lymph node cancer called lymphoma, a tumor of the nasal passages called nasopharyngeal carcinoma (NPC), a tumor of a particular type of muscle called leiomyosarcoma (LMS) or a condition called severe…
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder, Nasopharyngeal Carcinoma
- Trial name
- MALTED (NCT01447056)
- Testing
- LMP specific T cells
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Carcinoma
Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal…
- Trial name
- NCT03427359
- Testing
- cisplatin, capecitabine
- Volunteers
- 65 people
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course…
- Trial name
- NCT07373990
- Testing
- tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2)
- Volunteers
- 418 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma
The primary objective of this study is to determine the overall survival in patients with stage II (T1-2N1M0) NPC treated with concurrent chemotherapy and radiotherapy.
- Trial name
- NCT00817258
- Testing
- cisplatin, 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Nasopharyngeal Neoplasms, Stomatitis
Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). The most frequently occurred radiation-related side effect is probably the radiation-induced oral mucositis (OM), which affects up to 100% of…
- Trial name
- NCT02735317
- Testing
- Oral Ulcer Gargle (FORRAD®), Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Yun-fei Xia
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.
- Trial name
- NCT04978012
- Testing
- Fluzoparib and Camrelizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Brain Necrosis
Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
It is hypothesized that excessive generation of free radicals involves in the pathogenesis of radiation-induced brain necrosis. This study therefore evaluated the effect of free radical scavenger, edaravone, on radiation-induced…
- Trial name
- NCT01865201
- Testing
- Edaravone, Common fundamental management
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04437329
- Testing
- Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT07101744
- Testing
- Iparomlimab and Tuvonralimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Oligometastasis
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease.
- Conditions
- Nasopharyngeal Carcinoma, Oligometastasis, Radiotherapy
- Trial name
- NCT04221516
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Carcinoma
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
The purpose of this study is to verify that induction gemcitabine and cisplatin plus intensity-modulated radiotherapy (IMRT) is non-inferior to concurrent weekly cisplatin plus IMRT for patients with locoregionally advanced…
- Trial name
- NCT02460887
- Testing
- Gemcitabine, cisplatin, Intensity-modulated Radiotherapy
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Circulating Tumor Cell, Oropharyngeal Cancer
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Head and neck cancers (HNSCC) are primarily squamous cell cancers represented by tumors of the upper aerodigestive tract. Locally advanced stages (stages III and IV) account for 50 to 70% of all presentations.
- Trial name
- CTCO (NCT04696744)
- Testing
- CTC detection
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Nasopharyngeal Carcinoma, De-escalation Therapy
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
This prospective trial aims to enroll patients with stage III-IVA (AJCC 8th,) locoregionally advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06675214
- Testing
- Full course of PD-1/PD-L1 blockades, Cisplatin-based induction chemotherapy, Standard-dose IMRT
- Where
- China
- Volunteers
- 586 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03854838
- Testing
- Tolipalimab, Reirradiation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nasopharynx Cancer
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
This research aims to assess both effectiveness and safety of combining R-GEP regimen comprising gemcitabine, recombinant human endostatin, and cerexinib with low- and high-dose radiotherapy in managing unresectable recurrent…
- Trial name
- NCT06611826
- Testing
- GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy
- Volunteers
- 41 people
- Sponsor
- Zhejiang Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.